By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
vantagefeed.comvantagefeed.comvantagefeed.com
Notification Show More
Font ResizerAa
  • Home
  • Politics
  • Business
  • Tech
  • Health
  • Environment
  • Culture
  • Caribbean News
  • Sports
  • Entertainment
  • Science
Reading: Google DeepMind Launches AlphaProteo for AI Drug Design
Share
Font ResizerAa
vantagefeed.comvantagefeed.com
  • Home
  • Politics
  • Business
  • Tech
  • Health
  • Environment
  • Culture
  • Caribbean News
  • Sports
  • Entertainment
  • Science
Search
  • Home
  • Politics
  • Business
  • Tech
  • Health
  • Environment
  • Culture
  • Caribbean News
  • Sports
  • Entertainment
  • Science
Have an existing account? Sign In
Follow US
vantagefeed.com > Blog > Health > Google DeepMind Launches AlphaProteo for AI Drug Design
Google DeepMind Launches AlphaProteo for AI Drug Design
Health

Google DeepMind Launches AlphaProteo for AI Drug Design

Vantage Feed
Last updated: September 11, 2024 4:23 am
Vantage Feed Published September 11, 2024
Share
SHARE

Google DeepMind announced the launch of AlphaProteo, an AI system that helps biology and health researchers design new high-strength proteins that bind precisely and strongly to target molecules.

AlphaProteo was trained on the Protein Data Bank (PDB), enabling breakthroughs in science and education by providing access and tools for exploring, visualizing, and analyzing experimentally determined 3D structures from the PDB archive.

AlphaProteo generates candidate proteins that bind to a target based on the structure of the target molecule and a set of preferred binding sites on that molecule.

The tech giant said the binder has the potential to open up new areas of research in drug development and diagnostic biosensors.

“AlphaProteo can generate novel protein binders for a range of target proteins, including VEGF-A, which is associated with cancer and diabetic complications. This is the first time that an AI tool has successfully designed a protein binder for VEGF-A,” Google DeepMind’s protein design and wet lab teams said in a blog post.

“AlphaProteo achieved higher experimental success rates and 3-300-fold better binding affinities for the seven target proteins we tested than the best existing methods.”

To test AlphaProteo, the AI’s developers designed binders for a range of target proteins, including “two viral proteins involved in infection, BHRF1 and the SARS-CoV-2 spike protein receptor binding domain, SC2RBD, as well as five proteins involved in cancer, inflammation and autoimmune diseases: IL-7Rɑ, PD-L1, TrkA, IL-17A and VEGF-A.”

The binding success rate for one of the viral targets, BHRF1, averaged 88%, 10 times higher than previous methods.

The Google DeepMind Web Lab team collaborated with external research groups, including researchers from the Francis Crick Institute, and the data confirmed that AlphaProteo binders prevented SARS-CoV-2 from infecting human cells.

AlphaProteo has demonstrated the ability to reduce the time required for initial experimentation with protein binders for a variety of applications.

But despite the breakthroughs, the researchers noted that AI systems have limitations.

For example, AlphaProteo did not produce a suitable binder for TNFα, a protein associated with autoimmune diseases such as rheumatoid arthritis.

“Computational analysis showed that designing binders against TNFɑ is extremely challenging, so we chose TNFɑ to pose a strong challenge to AlphaProteo. We will continue to improve and extend the capabilities of AlphaProteo with the goal of ultimately addressing such challenging targets,” the authors write.

The AlphaProteo research team plans to collaborate with the scientific community to observe the impact of AlphaProteo on other biological problems and to further understand its limitations.

Additionally, the team has been exploring its drug design applications at Isomorphic Labs.

Larger trends

In June, Google Research and Google DeepMind Published a paper It announced the creation of a new LLM for drug discovery and therapeutic development called Tx-LLM, a tweak of Med-PaLM 2.

The tech giant Med-PaLM 2 is a generative AI technology that uses Google’s LLM to answer medical questions.

In May, A study conducted by Google Research in collaboration with Google DeepMind revealed that the tech giant has expanded the capabilities of its AI models for Med-Gemini-2D, Med-Gemini-3D, and Med-Gemini Polygenic.

Google said it has fine-tuned Med-Gemini’s capabilities using data from histopathology, dermatology, 2D and 3D radiology, genomics and ophthalmology.

In 2023, Google MedLM is a set of two foundational models built on Med-PaLM 2, designed to answer medical questions, generate insights from unstructured data, and summarize medical information.

While piloting LLM in healthcare organizations, the company said it learned that the most effective AI models are designed to address specific use cases.

As a result, a large-scale model of MedLM will be created to handle complex tasks, and another medium-scale model that can be fine-tuned and expanded across a range of tasks.

The HIMSS Healthcare Cybersecurity Forum is scheduled to take place October 31-November 1 in Washington, DC. More information and registration.

You Might Also Like

Judge approves 23andMe sales in privacy disputes

Simple Mayo Recipe: My View on Classics

7 tips on how to avoid stress affect your weight

Johnson & Johnson partners with AWS’ Nvidia to fund AI Surgical Tech

What to do when you get off track (without trying again)

TAGGED:AlphaProteoDeepMindDesigndrugGooglelaunches
Share This Article
Facebook Twitter Email Print
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!

Subscribe my Newsletter for new posts, tips & new Articles. Let's stay updated!

Popular News
Nearly 100 killed in Israeli airstrikes on Gaza shelters
Business

Nearly 100 killed in Israeli airstrikes on Gaza shelters

Vantage Feed Vantage Feed August 11, 2024
The star winked and disappeared from sight. Is it a “failed supernova”?
How Trump’s sudden change in tariff policy is affecting one small clothing manufacturer in New York City: “Everyone is horrifying”
A day in the life of a MoveOn organizer who travels around the country distributing ice cream
CBI must engage with Academia & Industries and acquire changes to AI injection: Vaishnaw
- Advertisement -
Ad imageAd image
Global Coronavirus Cases

Confirmed

0

Death

0

More Information:Covid-19 Statistics

Importent Links

  • About Us
  • Privacy Policy
  • Terms of Use
  • Contact
  • Disclaimer

About US

We are a dedicated team of journalists, writers, and editors who are passionate about delivering high-quality content that informs, educates, and inspires our readers.

Quick Links

  • Home
  • My Bookmarks
  • About Us
  • Contact

Categories & Tags

  • Business
  • Science
  • Politics
  • Technology
  • Entertainment
  • Sports
  • Environment
  • Culture
  • Caribbean News
  • Health

Subscribe US

Subscribe my Newsletter for new posts, tips & new Articles. Let's stay updated!

© 2024 Vantage Feed. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?